Appendix
← Clinical Reader
Cardiology

Tafamidis

Tafamidis is an oral medication for treating cardiomyopathy and peripheral neuropathy due to transthyretin amyloidosis (ATTR). It is a transthyretin stabilizer and has been shown to reduce disease progression and mortality significantly. This activity will highlight the current indications, mechanism of action, dosage, contraindications, and other key factors (e.g., off-label uses, dosing, pharmacodynamics, pharmacokinetics, monitoring, relevant interactions) of tafamidis in a clinical setting p

v1 · Reviewed Nov 7, 2026 by Automated Clinical Reviewer (Strict Verbatim v1)
  • Cardiomyopathy associated with ATTR amyloidosis (ATTR-CM) is debilitating and has a median survival of only 2 to 6 years.
  • Early diagnosis is critical because of the recent availability of targeted treatment, which is more effective when instituted early in the disease course.
  • Tafamidis should not be given in patients with NYHA class IV symptoms, 6-minute walk distance <100 m, and severe renal dysfunction (estimated glomerular filtration rate < 25 ml per minute per 1.73 m^2) as these patients were not studied in the ATTR-ACT trial.
  • The disease is usually suspected based on symptoms, electrocardiogram (ECG), echocardiography, cardiac biomarkers, or magnetic resonance imaging (MRI).
  • Suspected cases of cardiac amyloidosis should undergo screening for monoclonal protein to rule out AL amyloidosis (light chain), followed by myocardial scintigraphy or cardiac biopsy as needed.
  • The involvement of a nuclear medicine expert is essential because scintigraphy by 99mtechnetium compound is the mainstay of an early and non-invasive diagnosis of ATTR-CM.
  • In case of any doubt, endomyocardial biopsy and evaluation by an experienced pathologist remain the gold standard of diagnosis.
  • Genotyping is essential after diagnosis as a TTR variant requires genetic counseling from the family members.
  • Tafamidis is an oral medication for treating cardiomyopathy and peripheral neuropathy due to transthyretin amyloidosis (ATTR).
  • In May 2019, the FDA approved tafamidis to treat ATTR cardiomyopathy (ATTR-CM) of both wild and hereditary types to reduce cardiovascular hospitalizations and mortality.
  • In 2016, the first European consensus on transthyretin familial amyloid polyneuropathy recommended tafamidis as the standard of care in stage 1 ATTR-PN (polyneuropathy), replacing the liver transplantation.
  • There is no absolute contraindication to the use of tafamidis except hypersensitivity to the active substance (tafamidis or tafamidis meglumine) or any inactive ingredients present in the capsule.
  • Tafamidis is not recommended during pregnancy or breastfeeding, and for women of childbearing potential not using contraception.
  • Due to sorbitol in the capsules, it should not be given to patients with hereditary fructose intolerance.
  • Tafamidis should not be given in patients with liver transplants and should be discontinued after liver transplants.
  • Tafamidis should not be given in patients with NYHA class IV symptoms, 6-minute walk distance <100 m, and severe renal dysfunction (estimated glomerular filtration rate < 25 ml per minute per 1.73 m^2) as these patients were not studied in the ATTR-ACT trial.
  • Dose adjustment may be required when used with substrates of breast cancer resistant protein (BCRP) transporter (e.g., methotrexate, rosuvastatin, imatinib).
  • Avoid the combination of tafamidis with alpelisib, berotralstat, cladribine, ubrogepant, pazopanib, rimegepant, or topotecan.
  • The success of ATTR amyloidosis treatment with tafamidis is monitored and assessed by echocardiograms, cardiac magnetic resonance imaging (MRI), and scintigraphy with bone tracers to diagnose infiltrative cardiomyopathy.
  • Liver function test (LFT)
  • Renal function test (RFT)
  • Complete blood count (CBC)
  • Thyroid function test
  • Prothrombin time
  • Biomarkers of heart failure (NT-proBNP and Troponin I)
  • Electrocardiogram (EKG)- Low voltage in the limb leads and/or a pseudo-infarct pattern in the precordial leads.
  • review
    Tafamidis. StatPearls [Internet] — Bhupendra Verma, Preeti Patel — StatPearls Publishing, 2023

Decision support only. Verify against local protocols and current labeling. Source: www.ncbi.nlm.nih.gov